Q1 EPS Estimate for Jasper Therapeutics Boosted by Analyst

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Analysts at HC Wainwright boosted their Q1 2026 earnings estimates for Jasper Therapeutics in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.37) per share for the quarter, up from their previous estimate of ($0.79). The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share. HC Wainwright also issued estimates for Jasper Therapeutics’ Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($1.09) EPS, FY2028 earnings at ($0.85) EPS and FY2029 earnings at ($0.78) EPS.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.47.

JSPR has been the subject of several other reports. Rodman & Renshaw began coverage on shares of Jasper Therapeutics in a research note on Tuesday, January 13th. They set a “buy” rating and a $17.00 price objective for the company. UBS Group began coverage on shares of Jasper Therapeutics in a research report on Monday, March 23rd. They set a “neutral” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Jasper Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $19.88.

Jasper Therapeutics Stock Down 8.7%

JSPR opened at $0.80 on Thursday. The firm’s 50-day moving average price is $1.30 and its 200-day moving average price is $1.76. The company has a market cap of $22.38 million, a P/E ratio of -0.17 and a beta of 3.20. Jasper Therapeutics has a 52-week low of $0.80 and a 52-week high of $7.19.

Institutional Investors Weigh In On Jasper Therapeutics

Institutional investors have recently bought and sold shares of the business. Knott David M Jr increased its holdings in shares of Jasper Therapeutics by 5.8% in the 4th quarter. Knott David M Jr now owns 181,389 shares of the company’s stock valued at $332,000 after purchasing an additional 10,000 shares during the period. Acadian Asset Management LLC bought a new position in Jasper Therapeutics in the 1st quarter worth approximately $46,000. Marex Group plc acquired a new position in Jasper Therapeutics during the 2nd quarter worth $74,000. Engineers Gate Manager LP acquired a new position in Jasper Therapeutics during the 2nd quarter worth $78,000. Finally, Renaissance Technologies LLC increased its stake in shares of Jasper Therapeutics by 9.0% in the 4th quarter. Renaissance Technologies LLC now owns 227,183 shares of the company’s stock valued at $416,000 after buying an additional 18,683 shares during the period. 79.85% of the stock is currently owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.